Association of sodium‐glucose cotransporter 2 inhibitors with risk of incident dementia and all‐cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks
Authors' conclusion
The use of SGLT-2 inhibitor was associated with a lower risk of incident dementia and all-cause mortality in older adults with T2D compared to DPP-4 inhibitor and GLP-1 RA.
Study context
- Population
- Patients with T2D aged ≥50 years, registered January 2012–December 2022, without history of dementia, after ≥12 months of glucose-lowering drugstwo matched cohorts
- Exposure
- SGLT2i vs DPP-4i, and SGLT2i vs GLP-1 RA
- SGLT-2 inhibitors (cohort 1)n = 193,948
- SGLT-2 inhibitors (cohort 2)n = 165,566
- Outcome
- Incident dementia and all-cause mortality
Methodological detailsactive-comparator, propensity score matched, TriNetX electronic health records network
- Active-comparator
- Propensity score matched
- TriNetX electronic health records network
Main finding
As reported in the abstract
Hazard ratio (95% CI)
SGLT-2 inhibitors vs DPP-4 inhibitorsdementia; metformin + SGLT-2ivs metformin + DPP-4i cohort
0.62(0.59–0.65)
SGLT-2 inhibitors vs DPP-4 inhibitorsall-cause mortality; metformin + SGLT-2ivs metformin + DPP-4i cohort
0.54(0.52–0.56)
SGLT-2 inhibitors vs GLP-1 RAsdementia; metformin + SGLT-2ivs metformin + GLP-1 RA cohort
0.92(0.87–0.98)
SGLT-2 inhibitors vs GLP-1 RAsall-cause mortality; metformin + SGLT-2ivs metformin + GLP-1 RA cohort
0.88(0.85–0.91)
Observational data: associations, not effects.
Original publication
Association of sodium‐glucose cotransporter 2 inhibitors with risk of incident dementia and all‐cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks. Diabetes Obes Metab. Published 9 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →